Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES

Vaccine

Volumn 32, Issue 39, 2014, Pages 5013-5018

  Lee, Sung Jae ^a   Newman, Peter A ^b   Duan, Naihua ^c   Cunningham, William E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acceptability of healthcare; AIDS vaccine; Altruism; Attitudes; Risk compensation; Scale development

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASSOCIATION; ATTITUDE TO HEALTH; BISEXUAL FEMALE; BISEXUAL MALE; DRUG USE; EDUCATIONAL STATUS; FEMALE; HEALTH CARE FACILITY; HETEROSEXUALITY; HIGH RISK POPULATION; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; RELIABILITY; RISK ASSESSMENT; UNITED STATES; VACCINATION; VULNERABLE POPULATION; ALTRUISM; HIV INFECTIONS; PATIENT ATTITUDE; PSYCHOLOGY; TRUST;

ADULT; AIDS VACCINES; ALTRUISM; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; LOS ANGELES; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; TRUST; VACCINATION; VULNERABLE POPULATIONS;

EID: 84906100193     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.018     Document Type: Article

References (46)

1. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Eng J Med 2009, 361:2209-2220.
2. National Institute of Allergy and Infectious Diseases Research highlights: post-RV144/Thai trial research update August 27, 2012, Available at .
3. Weinbaum C., Billah K., Mast E.E., CDC Hepatitis B vaccination coverage among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 2006, 55:509-511.
4. Centers for Disease Control and Prevention National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wky Rep 2013, 62:685-693.
5. Newman P.A., Logie C.H., Doukas N., Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect 2013, 89:568-574.
6. Newman P.A., Duan N., Rudy E.T., Anton P.A. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?. AIDS Patient Care STDs 2004, 18:691-701.
7. Bearman P. Just-so stories: vaccines, autism, and the single-bullet disorder. Soc Psyhol Q 2010, 73:112-115.
8. Roberts K.J., Newman P.A., Duan N., Rudy E.T. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Nat Med Assoc 2005, 97:1662-1671.
9. Omer S.B., Salmon D.A., Orenstein W.A., deHart M.P., Halsey N. Vaccine refusal, mandatory immunization and the risks of vaccine-preventable diseases. N Eng J Med 2009, 360:1981-1988.
10. Omer S.B., Richards J.L., Ward M., Bednarczyk R.A. Vaccination policies and rates of exemption from immunization, 2005-2011. N Eng J Med 2012, 367:1170-1171.
11. Nature Immunology A case of junk science, conflict and hype. Nat Immunol 2008, 9:1317. (accessed February 24, 2014). http://www.nature.com/ni/journal/v9/n12/full/ni1208-1317.html.
12. Newman P.A., Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24:1749-1756.
13. Liau A., Zimet G.D., Fortenberry J.D. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis 1998, 25(2):76-81.
14. Zimet G.D., Perkins S.M., Sturm L.A., Bair R.M., Juliar B.E., Mays R.M. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005, 37(3):179-186.
15. Zimet G.D., Blythe M.J., Fortenberry J.D. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS 2000, 11(3):143-149.
16. Zimet G.D., Fortenberry J.D., Blythe M.J. Adolescents' attitudes about HIV immunization. J Pediatr Psychol 1999, 24(1):67-75.
17. Chang M.L., Vitek C., Esparza J., WHO-UNAIDS-CDC Public health consideration for the use of a first generation HIV vaccine: report from a WHO-UNAIDS-CDC Consultation, Geneva, 20-21 November 2002. AIDS 2003, 17:W1-W10.
18. Newman P.A., Lee S.J., Duan N., Rudy E.T., Nakazono T.K., Boscardin J., et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res 2009, 44:2167-2179.
19. Blower S.M., McLean A.R. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994, 265:1451-1454.
20. Newman P.A., Duan N., Lee S.J., Rudy E.T., Seiden D.S., Kakinami L., et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006, 24:2094-2101.
21. Costello A.B., Osborne J. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. PARE 2005, 10(7).
22. Tabachnick B.G., Fidell L.S. Using multivariate statistics 2001, Allyn & Bacon, Needham Heights, MA. 4th ed.
23. Comrey A.L., Lee H.B. A first course in factor analysis 1992, Erlbaum, Hillside, NJ. 2nd ed.
24. Lee S.-J., Newman P.A., Comulada W.S., Cunningham W.E., Duan N. Use of conjoint analysis to assess HIV vaccine acceptability in three diverse communities: feasibility of an innovation in the assessment of consumer healthcare preferences. Int J STD AIDS 2012, 23:235-241.
25. Nunally J.C. Psychometric theory 1978, McGraw-Hill, New York, NY.
26. Hair J., Anderson R., Tatham R., Black W. Multivariate data analysis 2006, Pearson/Prentice Hall, Inc., Upper Saddle River, NJ.
27. Moss S.C., Prosser H., Costello H., Simpson N., Patel P., Rowe S., et al. Reliability and validity of the PAS-ADD Checklist for detecting psychiatric disorders in adults with intellectual disability. J Intellect Disabil Res 1998, 42:173-183.
28. Eaton L.A., Kalichman S.C. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007, 4(4):165-172.
29. Hershey J.C., Asch D.A., Thumasathit, Meszaros J., Waters V.V. The roles of altruism, free riding, and bandwagoning in vaccination decisions. Organ Behav Hum Decis Process 1994, 59:177-187.
30. Woolf S.H. The meaning of translational research and why it matters. JAMA 2008, 299:211-213.
31. Shim E., Chapman G.B., Townsend J.P., Galvani A.P. The influence of altruism on influenza vaccination decisions. J R Soc Interface 2012, 9:2234-2243.
32. Newman P.A., Roungprakhon S., Tepjan S., Yim S., Walisser R. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Global Public Health 2012, 7:1009-1024.
33. Betsch C., Sachse K. Debunking vaccination myths: strong risk negations can increase perceived vaccination risks. Health Psychol 2013, 32:146-155.
34. Ravert R.D., Zimet G.D. College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav 2009, 33:391-399.
35. Van De Ven P., Bartholow B., Rawstorne P., Crawford J., Kippax S., Grulich A., et al. Scaling HIV vaccine attitudes among gay men in Sydney, Australia. AIDS Res Hum Retroviruses 2002, 18:1333-1337.
36. Bartholow B.N., Buchbinder S., Celum C., Goli V., Koblin B., Para M., et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005, 39:90-101.
37. Gray G.E., Metch B., Churchyard G., Mlisana K., Nchabeleng M., Allen M., et al. Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?. Vaccine 2013, 31(16):2089-2096.
38. Lampinen T.M., Chan K., Remis R.S., Merid M.F., Rusch M., Vincelette J., et al. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. CMAJ 2005, 172(4):479-483.
39. Newman P.A., Daley A., Halpenny R., Loutfy M. Community heroes for 'high-risk' pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008, 26:1091-1097.
40. Ott M.A., Alexander A.B., Lally M., Steever J.B., Zimet G.D. Preventive misconception and adolescents' knowledge about HIV vaccine trials. J Med Ethics 2013, 39:765-771. Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions.
41. Meyer J. County did not OK AIDS vaccine study, report says. Los Angeles Times January 30, 1998, Available at 〈http://articles.latimes.com/1998/jan/30/local/me-13649/2〉 (accessed May 19, 2014).
42. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004, 18:2235-2242.
43. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities. J Acquir Immune Defic Syndr 2006, 41(2):210-217.
44. Newman P.A., Lee S.-J., Rudy E.T., Diamant A., Duan N., Nakazano T., et al. Endorsement of compulsory HIV vaccination policy among populations at high risk of HIV exposure (LA VOICES). Prev Sci 2014, 15:428-435.
45. Quadri-Sheriff M., Hendrix K.S., Downs S.M., Sturm L.A., Zimet G.D., Finnell S.M. The role of herd immunity in parents' decision to vaccinate children: a systematic review. Pediatrics 2012, 130(3):522-530.
46. Bridges J.F. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2003, 2(4):213-224.